4.2 Review

HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer

期刊

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
卷 47, 期 3, 页码 893-913

出版社

KARGER
DOI: 10.1159/000490131

关键词

Long non-coding RNAs; HOTAIR; Cancers; Biomarkers; Therapeutic targets

资金

  1. National Nature Scientific Foundation of China [81272614, 81403216, 81703551]
  2. Science and Technology Program of Guangzhou [201607010385]
  3. Discipline of Integrated Chinese and Western Medicine in Guangzhou University of Chinese Medicine [A1-Af-D018161Z1513]
  4. Special Science and Technology Join Fund from Guangdong Provincial Department of Science and Technology-Guangdong Academy of Traditional Chinese Medicine [2014A020221024, 2017A050506042]
  5. Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine [YK2013B2N13, YN2015MS19]

向作者/读者索取更多资源

Long non-coding RNAs (LncRNAs) represent a novel class of noncoding RNAs that are longer than 200 nucleotides without protein-coding potential and function as novel master regulators in various human diseases, including cancer. Accumulating evidence shows that lncRNAs are dysregulated and implicated in various aspects of cellular homeostasis, such as proliferation, apoptosis, mobility, invasion, metastasis, chromatin remodeling, gene transcription, and post-transcriptional processing. However, the mechanisms by which lncRNAs regulate various biological functions in human diseases have yet to be determined. HOX antisense intergenic RNA (HOTAIR) is a recently discovered lncRNA and plays a critical role in various areas of cancer, such as proliferation, survival, migration, drug resistance, and genomic stability. In this review, we briefly introduce the concept, identification, and biological functions of HOTAIR. We then describe the involvement of HOTAIR that has been associated with tumorigenesis, growth, invasion, cancer stem cell differentiation, metastasis, and drug resistance in cancer. We also discuss emerging insights into the role of HOTAIR as potential biomarkers and therapeutic targets for novel treatment paradigms in cancer. (C) 2018 The Author(s) Published by S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据